Engineered oncolytic adenovirus Ad-TD-nsIL12 is demonstrating encouraging results in two early-phase clinical trials targeting diffuse intrinsic pontine glioma (DIPG), a pediatric brain tumor with dismal prognosis. This viral immunotherapy is designed to selectively replicate in cancer cells and stimulate local immune responses. Initial findings suggest potential therapeutic benefit in this otherwise treatment-refractory malignancy, providing a foundation for further development of viral oncolytic strategies in pediatric neuro-oncology.